PT-141 (Bremelanotide)
A melanocortin receptor agonist that acts centrally on sexual arousal pathways rather than on blood flow directly.
Research status: FDA-approved for hypoactive sexual desire disorder in women.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Selected references
- Obstetrics & Gynecology · 2019 Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
- International Journal of Impotence Research · 2004 PT-141: a melanocortin agonist for the treatment of sexual dysfunction
- Journal of Sexual Medicine · 2006 An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
- U.S. FDA · 2019 Vyleesi (bremelanotide) Prescribing Information
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
Related in Hormone